Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback